Aprea Therapeutics, Inc. (APRE)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
D
Pipeline Grade

Financial Position (from SEC Filings)

$46.5M
Cash & Equivalents
$2.8M
Quarterly Burn Rate
51 mo
Est. Cash Runway
$9M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT04905914 Study Of ATRN-119 In Patients With Advanced Solid Tumors PHASE2 Active Not Recruiting 132

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for APRE.

SEC EDGAR Filings

All SEC filings for Aprea Therapeutics, Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.